Vaxon-Biotech Announces Phase I Study Results for VX-001 Immunotherapy In Cancer Patients
Vaxon-Biotech today announces that it has completed the phase I trial of its candidate vaccine VX-001. The trial was conducted at Heraklion University Hospital in Greece. VX-001 was well-tolerated, stimulated T-cell immunity, and continues to show clinical benefits in participating patients.